[1] GORE R,CHUGH P K,TRIPATHI C D,et al.Pediatric off-label and unlicensed drug use and its implications[J].Curr Clin Pharmacol,2017,12(1):18-25.
[2] MIAN A N,SCHWARTZ G J.Measurement and estimation of glomerular filtration rate in children[J].Adv Chronic Kidney Dis,2017,24(6):348-356.
[3] PERICO N,ASKENAZI D,CORTINOVIS M,et al.Maternal and environmental risk factors for neonatal AKI and its long-term consequences[J].Nature Reviews Nephrology,2018,14(11):688-703.
[4] CHEN N,ALEKSA K,WOODLAND C,et al.Ontogeny of drug elimination by the human kidney[J].Pediatr Nephro,2006,21(2):160-168.
[5] WIDMER N,CSAJKA C,WERNER D,et al.Principles of therapeutic drug monitoring[J].Rev Med Suisse,2008,4(165):1644-1648.
[6] ATKINSON A J,Jr. HUANG S M.Nephropharmacology:drugs and the kidney[J].Clin Pharmacol Ther,2009,86(5):453-456.
[7] ARDISSINO G,DACCO V,TESTA S,et al.Epidemiology of chronic renal failure in children:data from the ItalKid project[J].Pediatrics,2003,111(4 Pt 1):e382-387.
[8] WONG C J,MOXEY-MIMS M,JERRY-FLUKER J,et al.CKiD(CKD in children) prospective cohort study:a review of current findings[J].Am J Kidney Dis,2012,60(6):1002-1011.
[9] CHAN J C,WILLIAMS D M,ROTH K S.Kidney failure in infants and children[J].Pediatr Rev,2002,23(2):47-60.
[10] BAILEY D,PHAN V,LITALIEN C,et al.Risk factors of acute renal failure in critically ill children:a prospective descriptive epidemiological study[J].Pediatr Crit Care Med,2007,8(1):29-35.
[11] MOFFETT B S,GOLDSTEIN S L.Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children[J].Clin J Am Soc Nephrol,2011,6(4):856-863.
[12] HARER M W,CHARLTON J R,TIPPLE T E,et al.Preterm birth and neonatal acute kidney injury:implications on adolescent and adult outcomes[J].J Perinatol,2020,40(9):1286-1295.
[13] GOSWAMI E,OGDEN R K,BENNETT W E,et al.Evidence-based development of a nephrotoxic medication list to screen for acute kidney injury risk in hospitalized children[J].Am J Health Syst Pharm,2019,76(22):1869-1874.
[14] LUNDSTROM T S,SOBEL J D.Antibiotics for gram-positive bacterial infections:vancomycin,quinupristin-dalfopristin,linezolid,and daptomycin[J].Infectious Disease Clinics of North America,2004,18(3):651-668,
[15] de HOOG M,MOUTON J W,van den ANKER J N.Vancomycin:pharmacokinetics and administration regimens in neonates[J].Clinical Pharmacokinetics,2004,43(7):417-440.
[16] 盛长城，沈祥春，唐才林，等.基于胱抑素 C 评估肾功能的万古霉素群体药动学研究[J].中国药学杂志，2018，53(21)：1847-1855.
[17] FARBER B F,MOELLERING R C Jr.Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981[J].Antimicrobial Agents and Chemotherapy,1983,23(1):138-141.
[18] RYBAK M J,LOMAESTRO B M,ROTSCHAFER J C,et al.Vancomycin therapeutic guidelines:a summary of consensus recommendations from the infectious diseases society of America,the American society of health-system pharmacists,and the society of infectious diseases pharmacists[J].Clinical Infectious Diseases,2009,49(3):325-327.
[19] PAIS G M,LIU J,ZEPCAN S,et al.Vancomycin-induced kidney injury:animal models of toxicodynamics,mechanisms of injury,human translation,and potential strategies for prevention[J].Pharmacotherapy,2020,40(5):438-454.
[20] RYBAK M J,LE J,LODISE T P,et al.Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections:a revised consensus guideline and review by the American Society of Health-System Pharmacists,the Infectious Diseases Society of America,the Pediatric Infectious Diseases Society,and the Society of Infectious Diseases Pharmacists[J].Am J Health Syst Pharm,2020,77(11):835-864.
[21] ZHANG H,WANG Y,GAO P,et al.Pharmacokinetic characteristics and clinical outcomes of vancomycin in young children with various degrees of renal function[J].J Clin Pharmacol,2016,56(6):740-748.
[22] SMIT C,GOULOOZE S C,BRUGGEMANN R J M,et al.Dosing recommendations for vancomycin in children and adolescents with varying levels of obesity and renal dysfunction:a population pharmacokinetic study in 1892 children aged 1-18 years[J].AAPS J,2021,23(3):53.
[23] ARVIDSSON A,ALVAN G,ANGELIN B,et al Ceftriaxone:renal and biliary excretion and effect on the colon microflora[J].J Antimicrob Chemother,1982,10(3):207-215.
[24] SCHAAD U B,WEDGWOOD-KRUCKO J,TSCHAEPPELER H.Reversible ceftriaxone-associated biliary pseudolithiasis in children[J].Lancet,1988,2(8625):1411-1413.
[25] CHUTIPONGTANATE S,THONGBOONKERD V.Ceftriaxone crystallization and its potential role in kidney stone formation[J].Biochem Biophys Res Commun,2011,406(3):396-402.
[26] LI N,ZHOU X,YUAN J,et al.Ceftriaxone and acute renal failure in children[J].Pediatrics,2014,133(4):e917-922.
[27] PANNU N,NADIM M K.An overview of drug-induced acute kidney injury[J].Crit Care Med,2008,36(4 Suppl):S216-223.
[28] GOLDSTEIN S L,KIRKENDALL E,NGUYEN H,et al.Electronic health record identification of nephrotoxin exposure and associated acute kidney injury[J].Pediatric,2013,132(3):e756-767.
[29] BALESTRACCI A,EZQUER M,ELMO M E,et al.Ibuprofen-associated acute kidney injury in dehydrated children with acute gastroenteritis[J].Pediatr Nephro,2015,30(10):1873-1878.
[30] WHELTON A.Nephrotoxicity of nonsteroidal anti-inflammatory drugs:physiologic foundations and clinical implications[J].Am J Med,1999,106(5B):S13-S24.
[31] MEDOFF G,KOBAYASHI G S.Strategies in the treatment of systemic fungal infections[J].N Engl J Med,1980,302(3):145-155.
[32] SAWAYA B P,WEIHPRECHT H,CAMPBELL W R,et al.Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats[J].J Clin Invest,1991,87(6):2097-2107.
[33] KARADAG-ONCEL E,OZSUREKCI Y,YURDAKOK M,et al.Is liposomal amphotericin B really safety in neonates?[J].Early Hum Dev,2013,89(1):35-36.
[34] GOLDMAN R D,KOREN G.Amphotericin B nephrotoxicity in children[J].J Pediatr Hematol Onco l,2004,26(7):421-426.
[35] TURCU R,PATTERSON M J,OMAR S.Influence of sodium intake on amphotericin B-induced nephrotoxicity among extremely premature infants[J].Pediatr Nephrol,2009,24(3):497-505.
[36] ENGLUND J A,FLETCHER C V,BALFOUR H H Jr.Acyclovir therapy in neonates[J].J Pediatr,1991,119(1 Pt 1):129-135.
[37] McDANIEL B L,BENTLEY M L.The role of medications and their management in acute kidney injury[J].Integrated Pharmacy Research & Practice,2015,4:21-29.
[38] GUNNESS P,ALEKSA K,BENF J,et al.Acyclovir-induced nephrotoxicity:the role of the acyclovir aldehyde metabolite[J].Translational Research:The Journal of Laboratory and Clinical Medicine,2011,158(5):290-301.
[39] HANNA M H,ASKENAZI D J,SELEWSKI D T.Drug-induced acute kidney injury in neonates[J].Curr Opin Pediatr,2016,28(2):180-187.
[40] RAO S,ABZUG M J,CAROSONE-LINK P,et al.Intravenous acyclovir and renal dysfunction in children:a matched case control study[J].J Pediatr,2015,166(6):1462-1468.
[41] de ROSE D U,CAIROLI S,DIONISI M,et al.Therapeutic drug monitoring is a feasible tool to personalize drug administration in neonates using new techniques:an overview on the pharmacokinetics and pharmacodynamics in neonatal age[J].Int J Mol Sci,2020,21(16).
[42] MEIBOHM B,LAER S,PANETTA J C,et al.Population pharmacokinetic studies in pediatrics:issues in design and analysis[J].AAPS J,2005,7(2):E475-487.
[43] MAHARAJ A R,EDGINTON A N.Physiologically based pharmacokinetic modeling and simulation in pediatric drug development[J].CPT Pharmacometrics Syst Pharmacol,2014,3:e150.
[44] EMOTO C,FUKUDA T,JOHNSON T N,et al.Development of a pediatric physiologically based pharmacokinetic model for sirolimus:applying principles of growth and maturation in neonates and infants[J].CPT Pharmacometrics Syst Pharmacol,2015,4(2):e17.
[45] YANG F,TONG X,McCARVER D G,et al.Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model[J].J Pharmacokinet Pharmacodyn,2006,33(4):485-518.
[46] SANCHEZ-PINTO L N,GOLDSTEIN S L,SCHNEIDER J B,et al.Association between progression and improvement of acute kidney injury and mortality in critically ill children[J].Pediatr Crit Care Med,2015,16(8):703-710. |
